To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy

World Journal of Hepatology

Volumn 6, Issue 4, 2014, Pages 226-229

  Mekky, Mohamed A ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Hepatitis B virus; Immunotolerant phase; Liver biopsy; Nucleotide analogue; Polymerase chain reaction

Indexed keywords

EID: 84901242530     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i4.226     Document Type: Short Survey

References (32)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745 [PMID: 9392700]
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956 [PMID: 2834034]
3. Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ. Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol 2007; 13: 2104-2107 [PMID: 17465456]
4. Daniels G. A century of human blood groups. Wien Klin Wochenschr 2001; 113: 781-786 [PMID: 11732113]
5. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129 [PMID: 15014185]
6. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S55 [PMID: 19399792 DOI: 10.1002/hep.22898]
7. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500 [PMID: 18832247 DOI: 10.1056/NEJMra0801644]
8. Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, Chen PJ, Chen DS. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15: 770-776 [PMID: 1568717]
9. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-624 [PMID: 11584355]
10. Farci P, Quinti I, Farci S, Alter HJ, Strazzera R, Palomba E, Coiana A, Cao D, Casadei AM, Ledda R, Iorio R, Vegnente A, Diaz G, Tovo PA. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA 2006; 103: 8475-8480 [PMID: 16707577]
11. Chang MH, Hwang LY, Hsu HC, Lee CY, Beasley RP. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology 1988; 8: 374-377 [PMID: 3356419]
12. Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol 1993; 8: 470-475 [PMID: 8218997]
13. Hsu HC, Lin YH, Chang MH, Su IJ, Chen DS. Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens. Hepatology 1988; 8: 378-382 [PMID: 3356420]
14. Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, Chang MH, Chen DS. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 2010; 84: 3454-3463 [PMID: 20089644 DOI: 10.1128/ JVI.02164-09.]
15. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767 [PMID: 17928090]
16. Carey I, D'Antiga L, Bansal S, Longhi MS, Ma Y, Mesa IR, Mieli-Vergani G, Vergani D. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. J Virol 2011; 85: 2416-2428 [PMID: 21147914 DOI: 10.1128/JVI.01449-10]
17. Yalcin K, Degertekin H, Yildiz F, Celik Y. Markers of disease activity in chronic hepatitis B virus infection. Clin Invest Med 2003; 26: 27-34 [PMID: 12659467]
18. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
19. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver.. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/ s12072-008-9080-3]
20. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218]
21. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-S84 [PMID: 19399801 DOI: 10.1002/hep.22884]
22. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921-931 [PMID: 17678844]
23. Sanai FM, Babatin MA, Bzeizi KI, Alsohaibani F, Al-Hamoudi W, Alsaad KO, Al Mana H, Handoo FA, Al-Ashgar H, Alghamdi H, Ibrahim A, Aljumah A, Alalwan A, Altraif IH, Al-Hussaini H, Myers RP, Abdo AA. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol 2013; 11: 1493-1499.e2 [PMID: 23811251 DOI: 10.1016/j.cgh.2013.05.038]
24. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012; 61: 333-336 [PMID: 22147510 DOI: 10.1136/gutjnl-2011-300937]
25. Poddar U, Yachha SK, Agarwal J, Krishnani N. Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? J Viral Hepat 2013; 20: 311-316 [PMID: 23565612 DOI: 10.1111/jvh.12007]
26. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661 [PMID: 7477217]
27. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-1843 [PMID: 3569757]
28. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, Lok AS. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-1863 [PMID: 21618260 DOI: 10.1002/hep.24318]
29. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol 2013; 28: 1762-1769 [PMID: 23808759 DOI: 10.1111/jgh.12312]
30. Hu KQ, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM, Goodman ZD, Dau LO, Peschell KJ, Fagan EA, Flaherty JF. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroenterol 2010; 44: 510-516 [PMID: 20179614 DOI: 10.1097/ MCG.0b013e3181d34c65]
31. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10 [PMID: 12093239]
32. Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31: 1197-1203 [PMID: 23306359 DOI: 10.1016/j.vaccine.2012.12.074]